Data Dive: Unpacking Datopotomab Deruxtecan and Its Recent FDA Approval

In this episode of Lung Cancer Considered, host Dr. Narjust Florez is joined by Dr. Jacob Sands to discuss the recent approval of datopotamab deruxtecan for locally-advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy.